SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-017969
Filing Date
2024-04-04
Accepted
2024-04-04 16:31:24
Documents
6
Period of Report
2024-05-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20016521x2_def14a.htm DEF 14A 963216
2 logo_cytomx2.jpg GRAPHIC 31776
3 ny20016521x2-pc_1.jpg GRAPHIC 471762
4 ny20016521x2-pc_2.jpg GRAPHIC 537473
5 ny20016521x2_pvpchart01.jpg GRAPHIC 158682
6 ny20016521x2_pvpchart02.jpg GRAPHIC 141393
  Complete submission text file 0001140361-24-017969.txt   2810224
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37587 | Film No.: 24823540
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)